Trial site
Campbelltown Hospital
Campbelltown, New South Wales 2560, AustraliaNot linked to an institution yet
- 11running trials
- 14closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 28 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Completed11 trials
- Active, not recruiting6 trials
- Recruiting3 trials
- Not yet recruiting2 trials
- Terminated2 trials
- Withdrawn1 trial
- Lead sponsor
- Boehringer Ingelheim2 trials
- Canadian Cancer Trials Group2 trials
- Connect Biopharm LLC2 trials
- University of Sydney2 trials
- Amgen1 trial
- and 16 more
Running trials
Not yet recruiting
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
PRA-216 COPD Safety and Biomarker Study
NCT07730281· Phase 2· Prana Therapies Inc· Source
Contact: Nesiya Pallippattu Hassan
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NCT05701358· Population Health Research Institute· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source
Active, not recruiting
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
NCT04195139· Phase 2· University of Sydney· Source
Active, not recruiting
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
NCT03057106· Phase 2· Canadian Cancer Trials Group· Source
Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707· Phase 3· UMC Utrecht· Source
Contact: Cameron Green, MSc
Active, not recruiting
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
NCT02446444· Phase 3· University of Sydney· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
NCT06940154· Phase 2· Connect Biopharm LLC· Source
Completed
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
NCT06940141· Phase 2· Connect Biopharm LLC· Source
Completed
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
NCT06987643· Phase 2· EIP Pharma Inc· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047· Phase 2· Novo Nordisk A/S· Source
Completed
SBD121, a Synbiotic Medical Food for RA Management
NCT06005220· Solarea Bio, Inc· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· Phase 3· Hoffmann-La Roche· Source
Terminated
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
NCT05574010· Phase 1/2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source
Completed
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
NCT05425446· Phase 1· Chugai Pharmaceutical· Source
Completed
The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial
NCT05025852· Mount Sinai Hospital, Canada· Source
Terminated
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04921358· Phase 3· BeiGene· Source
Completed
Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)
NCT04902378· University of Calgary· Source
Completed
Preventing Adverse Cardiac Events in COPD
NCT03917914· Phase 3· The George Institute· Source
Completed
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
NCT03685448· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source
Completed
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT02273375· Phase 3· Canadian Cancer Trials Group· Source
Report an error